

## **DONALD H. PRITCHARD, M.D.**

---

### **PROFESSIONAL EXPERIENCE**

2007 – present

**SNBL Clinical Pharmacology Center**

Research Physician

Principal Investigator

2002 – 2007

**Covance Clinical Research Unit, Inc. Florida (formerly Radiant Research)**

Principal Investigator

Laboratory Director

1996 – 2006

**Crystal River Primary Care, Florida**

Physician, Internal Medicine

1996 – 2006

**Seven Rivers Regional Medical Center, Florida**

Active or Courtesy Staff – Department of Medicine

1996 – 2006

**Citrus Memorial Hospital, Florida**

Active or Courtesy Staff – Department of Medicine

1988 – 1995

**Internal Medicine Office, Rhode Island**

Physician, Internal Medicine

1988 - 1995

**Landmark Medical Center, Rhode Island**

Active Staff – Department of Medicine

1978 - 1980

**Nalco Chemical Company, Illinois**

Sales Representative

## **EDUCATION & TRAINING**

1985 – 1988

**Internal Medicine Residency**, Rhode Island Hospital/Brown University

1981 - 1985

**Doctor of Medicine**, The Chicago Medical School

1974 – 1977

**Bachelor of Science** with Distinction, University of Michigan

## **CERTIFICATIONS & PROFESSIONAL LICENSURE**

- Licensed Physician, Maryland 2007
- BLS Certified 2007
- ACLS Certified 2007
- Recertification – American Board of Internal Medicine 2005
- Geriatric Recognition Award, American Geriatric Society 1998
- Licensed Physician, Florida 1995
- Certification – American Board of Internal Medicine 1994
- Licensed Physician, Rhode Island (inactive) 1985
- National Board of Medical Examiners 1985

## **RESEARCH EXPERIENCE**

2007

- Phase IIIa, 26 week, open-label, multi-center, randomized, parallel trial to investigate efficacy and safety of inhaled mealtime insulin with the XXXX plus XXXX versus XXXX in Type 2 Diabetes
- Single Dose Pharmacokinetics and Safety/Tolerability of Pramipexole Transdermal Systems Compared to Oral XXXX in Healthy Volunteers
- Efficacy and safety of 2 mg/day of XXXX on Sleep Maintenance Insomnia with a sub-study of the effect of XXXX on stable Type II Diabetes Mellitus: a one year, multi center, randomized, double-blind, placebo-controlled study.
- Multi-center, randomized, double-blind active controlled, parallel group study to investigate plasma folate, red blood cell folate and homocysteine levels during a 24 week oral administration of an OC containing folate compared to OC alone

- A 52-Week, Randomized, Double-Blind, Parallel-group, Multi-center, Phase IIIB Study Comparing the Long-term Safety of XXXX Actuations Twice Daily to XXXX Actuations Twice Daily in Adult and Adolescent African American Subjects with Asthma
- A 10 week multicenter, randomized, double-blind, parallel-group, forced titration study using 24 hour ABPM to evaluate the efficacy of XXXX treatment regimen versus conventional treatment regimen with XXXX in patients with stage 2 hypertension
- A Multicenter, randomized, double-blind study to compare the efficacy and safety of patient-initiated XXXX to XXXX in immunocompetent adults with recurrent genital herpes
- A randomized, Double-Blind, Active-and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of XXXX Immediate-Release Formulation in Subjects Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease

2006

- A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of XXX and XXX Combination Therapy to XXX and XXX in Subjects with Mixed Dyslipidemia
- A Multicenter, Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of XXX in Combination with XXX in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone
- A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Examine Safety and Establish Proof of Concept with XXX in Patients with Type 2 Diabetes Mellitus
- Phase I Bioequivalence Study for XXX Phase II and Phase III Tablets
- A Double-Blind, Parallel-Two-Arm, Positive-Controlled 28-Day Outpatient Study in 72 Subjects, to Assess the Safety and Tolerability of a Swallowable XXX Only Tablet, Both Designed to Supplement Actonel Once a Week Administration, Each Administered Twice Daily in 28 Post-Menopausal Women and 8 Healthy Males Per Arm
- A Long-Term, Open-Label, Safety Extension Study of the Combination of XXX and XXX for subjects with Mixed Dyslipidemia
- A Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Kinetics of XXX in healthy male subjects
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Kinetics of once and twice daily portions of XXX with and without meals, in healthy, slightly overweight, male subjects

- An Open-Label Study to evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXX when co-administered with repeat doses of XXX in healthy adult subjects

2005

- A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of XXX in Patients with Osteoarthritis or Rheumatoid Arthritis
- A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of XXX Versus XXX in Patients with Rheumatoid Arthritis
- Safety of Topical Use of XXX in Humans; Determination of Clinical Responses and Serum Level of XXX
- Double-Blinded Study to Evaluate Immunogenicity of XXX Vaccine in Normal, Healthy Volunteers
- A 28-Week, Multicenter, Randomized, Active Controlled, Parallel Group Study to Evaluate the Effects of XXX in Comparison with XXX, for the Treatment of Patients with Hypertension, Uncontrolled by Hydrochlorothiazide monotherapy
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Effects on Lipids of 12 Weeks of 2 Doses of XXX in Subjects with Primary Hypercholesterolemia
- A Phase 3 Study of the Analgesic Efficacy and Safety of XXX A Parallel, Randomized, Double-Blind, 13-Week XXX and XXX Multicenter Study of XXX in Patients with Osteoarthritis of the Knee

2004

- Pharmacokinetics and Bioavailability Comparison of Immediate Release and Enteric XXX — A Double-Blind, Single Dose Crossover Phase I Study in Normal Volunteers
- A Multicenter, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Safety and Efficacy of an Oral Contraceptive Preparation Containing XXX for 6 Treatment Cycles in Women with Moderate Acne Vulgaris
- A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of XXX in Healthy Obese Men and Women

- An Open Label, Multiple Dose Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Between XXX on and XXX When Given Alone or in Combination in Healthy Volunteers
- A Study to Evaluate the Potential Effect of a Medium-Fat Meal on the Relative Bioavailability of Multiple Doses of XXX and XXX in Healthy Postmenopausal Women
- The Relative Bioavailability of Two Formulations of XXX Compared to Twice Weekly Application of XXX
- Effects of XXX on Vertebral Fracture Incidence and on Invasive Breast Cancer Incidence in Postmenopausal Women with Osteoporosis or with Low Bone Density without Osteoporosis
- A 6-week, randomized, double-blind, placebo-controlled, multicenter study, to assess the efficacy and safety of XXX and XXX in female patients with dyspepsia
- An open-label, multiple dose, randomized, three-period, crossover study in healthy volunteers to evaluate the pharmacokinetics of XXX and XXX when co-administered and administered alone
- A 12 month, randomized, open-label, multicenter, study to assess the long term safety of XXX alone and XXX alone or with optional addition of XXX in patients with essential hypertension
- A Randomized, Double-Blind, Placebo- and Positive-Controlled Phase 2A Study to Evaluate the Effect of Various Doses of XXX on Food Intake in Obese Subjects
- A Randomized, Open-Label Study Comparing the Efficacy and Safety of XXX to XXX in Patients with Pain From Osteoarthritis of the Knee

2003

- A Multi-center, Active-controlled XXX, Double-blind, Randomized, Sequential Escalating Dose Study to Assess Safety, Pharmacokinetics and Efficacy of XXX, XXX, and XXX mg Oral XXX Administered Monthly for Six Months in Postmenopausal Women with Low Bone Mineral Density
- A Replicate Design, Double-Blind, Randomized, Placebo Controlled Tolerance and Pharmacokinetics Study of XXX in Normal, Healthy Volunteers